| __timestamp | Neurocrine Biosciences, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 14400000 | 17345000000 |
| Thursday, January 1, 2015 | 33800000 | 17404000000 |
| Friday, January 1, 2016 | 35900000 | 17520000000 |
| Sunday, January 1, 2017 | 1254000 | 17175000000 |
| Monday, January 1, 2018 | 4889000 | 18407000000 |
| Tuesday, January 1, 2019 | 7400000 | 14425000000 |
| Wednesday, January 1, 2020 | 10100000 | 15121000000 |
| Friday, January 1, 2021 | 14300000 | 15867000000 |
| Saturday, January 1, 2022 | 23200000 | 15486000000 |
| Sunday, January 1, 2023 | 39700000 | 12472000000 |
| Monday, January 1, 2024 | 34000000 | 12827000000 |
Data in motion
In the ever-evolving pharmaceutical industry, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Novartis AG and Neurocrine Biosciences, Inc. from 2014 to 2023. Novartis, a global healthcare giant, consistently reported a cost of revenue averaging around $16 billion annually, with a notable peak in 2018. In contrast, Neurocrine Biosciences, a smaller biotech firm, showed a more dynamic trend, with costs rising from $1.4 million in 2014 to nearly $40 million in 2023, reflecting a growth rate of over 2,700%. This stark contrast highlights the scale and operational differences between established pharmaceutical leaders and emerging biotech companies. As the industry continues to innovate, understanding these financial dynamics is crucial for investors and stakeholders aiming to navigate the competitive landscape.
Analyzing Cost of Revenue: Novo Nordisk A/S and Neurocrine Biosciences, Inc.
Novartis AG vs Sanofi: Efficiency in Cost of Revenue Explored
Novartis AG vs Biogen Inc.: Efficiency in Cost of Revenue Explored
Cost Management Insights: SG&A Expenses for Novartis AG and Neurocrine Biosciences, Inc.
Novartis AG vs Jazz Pharmaceuticals plc: Efficiency in Cost of Revenue Explored
Novartis AG vs PTC Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Neurocrine Biosciences, Inc.
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Catalent, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Ionis Pharmaceuticals, Inc.
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.'s Expenses